MedTrace Logo

Impact of Hydrocortisone Administration on White Blood Cell Gene Expression in Patients With Severe Sepsis

NCT00185783 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2011-04-11

No results posted yet for this study

Summary

The purpose of this pilot study is to (1) examine the changes in gene expression in patients who suffer from severe sepsis and whose shock (inadequate oxygen delivery to vital organs) state does not respond to fluid and vasopressor administration, (2) to show that our sampling method of isolating RNA provides reliable and consistent data, (3) provide a basis for future gene expression studies in critically ill patients

Conditions

  • Sepsis
  • Relative Adrenal Insufficiency

Interventions

DRUG

Hydrocortisone Administration (Standard of Care Therapy)

Sponsors & Collaborators

  • University of Toronto

    collaborator OTHER

  • University of Colorado, Denver

    collaborator OTHER

  • Stanford University

    lead OTHER

Principal Investigators

  • Andrew J Patterson, M.D., Ph.D. · Stanford University, Dept. of Anesthesia, Division of Critical Care Medicine

  • Ann Weinacker, M.D., · Stanford University, Dept. of Medicine, Div. of Pulmonary and Critical Care Medicine

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-03-31
Primary Completion
2006-11-30
Completion
2006-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00185783 on ClinicalTrials.gov